JPRN-jRCTs041200107Recruiting未知
The effects of dapagliflozin on anemia of chronic kidney disease (Study A)
Hamano Takayuki0 sites96 target enrollmentStarted: March 8, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 96
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •(1) Those with CKD stage 3-4 and diabetes mellitus or heart failure with reduced ejection fraction, those with CKD without diabetes or heart failure with reduced ejection fration (eGFR 15-59 mL/min/1.73m2)
- •(2) Those on erythropoiesis stimulating agents (ESA) or hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors
- •(3) Those without iron deficiency (transferrin saturation >= 20% or ferritin >= 50 ng/mL)
- •(4) Those who are not on SGLT2 inhibitors
- •(5) Those who gave informed consent
- •(6) Age >= 20 years old at the time of consent (both men and women, and inpatients and outpatients)
- •(7) For those with heart failure with reduced ejection fraction, they should be on standard therapy for heart failure (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, or beta blockers)
Exclusion Criteria
- •(1) Those with history of allergy to dapagliflozin
- •(2) Those with severe ketoacidosis, hyperosmolar coma or precoma, or type 1 diabetes
- •(3) Those with hospitalization due to infection, surgery under general anesthesia, trauma requiring surgical intervention, gastrointestinal bleeding, transfusion, active malignancy within 3 months, or those expecting surgery within 3 months
- •(4) Those with non-adherence
- •(5) Pregnant or potentially pregnant women
- •(6) Those whom treating physicians judge inappropriate candidates for participating in the study
Investigators
Similar Trials
Recruiting
Not Applicable
The effects of dapagliflozin on anemia of chronic kidney disease (Study B)Chronic kidney disease stage 3-4 with anemia of chronic kidney diseaseDapagliflozin, diabetes mellitus, chronic kidney disease, anemia of chronic kidney disease, heart failure with reduced ejection fractionJPRN-jRCTs041200108Hamano Takayuki96
Active, not recruiting
Phase 1
Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory studyPatients with T2DM and hypertension aged 40 to 70 years (including)EUCTR2017-004889-10-DEniversity Hospital Tuebingen75
Recruiting
Phase 3
Effect of Dapagliflozin in The Prevention of Iodinated Contrast Media Induced Acute Kidney InjuryAcute kidney injury caused by iodinated contrast agents.Acute kidney failureIRCT20170609034406N11Tabriz University of Medical Sciences80
Not yet recruiting
Phase 4
Evaluating the effect of Dapagliflozin on Alanine Transaminase Levels in Type 2 Diabetic Patients with Non Alcoholic Fatty Liver Diseaseon Alcoholic SteatohepatitisNon Alcoholic SteatohepatitisMetabolic and Endocrine - DiabetesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonType 2 Diabetes MellitusACTRN12624000039583MTI Lady Reading Hospital192
Completed
Not Applicable
The effect of dapagliflozin in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trialAutosomal dominant polycystic kidney disease (ADPKD)JPRN-UMIN000046275Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine30